Oncology ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
